On Nov. 30, the U.S. Food and Drug Administration (FDA) approved Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Read more.
Most Recent Content
For Nurse Practitioners
Getting Covid Vaccine Won’t Hurt Pregnancy Chances; Getting Covid Could
Couples planning a pregnancy might be relieved to know that getting a Covid vaccine does not hurt their odds of conceiving, according to the...
